Evidence map›Paper›PMID 35335288›Full record

ArticleMolecules (Basel, Switzerland)2022

Wilmer H Perera, Alexander M Scherbakov, Galina I Buravchenko, Ekaterina I Mikhaevich, Suzana Guimarães Leitão, Paul Cos, Andrey E Shchekotikhin, Lianet Monzote, William N Setzer

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 6 countries.

Wilmer H PereraCAMAG Scientific, Inc., 515 Cornelius Harnett Drive, Wilmington, NC 28401, USA.ORCID 0000-0003-3607-8638
Alexander M ScherbakovDepartment of Experimental Tumor Biology, Blokhin N.N. National Medical Research Center of Oncology, 24 Kashirskoye sh., 115522 Moscow, Russia.ORCID 0000-0002-2974-9555
Galina I BuravchenkoLaboratory of Chemical Transformations of Antibiotics, Gause Institute of New Antibiotics, 11 B. Pirogovskaya St., 119021 Moscow, Russia.
Ekaterina I MikhaevichDepartment of Experimental Tumor Biology, Blokhin N.N. National Medical Research Center of Oncology, 24 Kashirskoye sh., 115522 Moscow, Russia.
Suzana Guimarães LeitãoFaculty of Pharmacy, Federal University of Rio de Janeiro, CCS, Bl. A, Ilha do Fundão, Rio de Janeiro 21941-902, Brazil.ORCID 0000-0001-7445-074X
Paul CosResearch Network Natural Products against Neglected Diseases (ResNetNPND), University of Münster, 48149 Münster, Germany.ORCID 0000-0003-4361-8911
Andrey E ShchekotikhinLaboratory of Chemical Transformations of Antibiotics, Gause Institute of New Antibiotics, 11 B. Pirogovskaya St., 119021 Moscow, Russia.ORCID 0000-0002-6595-0811
Lianet MonzoteResearch Network Natural Products against Neglected Diseases (ResNetNPND), University of Münster, 48149 Münster, Germany.ORCID 0000-0002-1958-809X
William N SetzerResearch Network Natural Products against Neglected Diseases (ResNetNPND), University of Münster, 48149 Münster, Germany.ORCID 0000-0002-3639-0528
University of Münster · DED. Mendeleyev University of Chemical Technology of Russia · RUGause Institute of New Antibiotics Russian Academy of Medical Sciences · RUUniversidade Federal do Rio de Janeiro · BRUniversity of Antwerp · BE

Funding

Russian Foundation for Basic Research 18-53-34005
6 · The paper itself

Abstract

In this study, the in vitro antimicrobial, antiparasitic, antiproliferative and cytotoxic activities of essential oil from Baccharis parvidentata Malag. (EO-Bp) and Lippia origanoides Kunth (EO-Lo) were explored. The relevant effects were observed against the parasitic protozoans Plasmodium falciparum, Trypanosoma cruzi, Trypanosoma brucei and Leishmania amazonensis (ranging 0.6 to 39.7 µg/mL) and malignant MCF-7, MCF-7/HT, 22Rv1, and A431 cell lines (ranging 6.1 to 31.5 µg/mL). In parallel, EO-Bp showed better selective indexes in comparison with EO-Lo against peritoneal macrophages from BALB/c mice and MRC-5 cell line. In conclusion, EO-Lo is known to show a wide range of health benefits that could be added as another potential use of this oil with the current study. In the case of EO-Bp, the wide spectrum of its activities against protozoal parasites and malignant cells, as well as its selectivity in comparison with non-malignant cells, could suggest an interesting candidate for further tests as a new therapeutic alternative.

Indexed as

BaccharisLippiaOils, VolatileTrypanosoma cruziAnimalsBrazilMiceOils, VolatileBaccharis parvidentatacancer cellsessential oilLippia origanoidesprotozoa

Identifiers

PMID35335288
PMCPMC8953750
OpenAlexW4220774306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.